Literature DB >> 22409989

Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency.

Eyal Grunebaum1, Ernest Cutz, Chaim M Roifman.   

Abstract

BACKGROUND: Inherited defects in the function of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many other cells and tissues.
OBJECTIVES: We sought to characterize the frequency and features of pulmonary alveolar proteinosis (PAP) in patients with ADA deficiency.
METHODS: Clinical and laboratory features of all patients with SCID caused by ADA deficiency in a single center were analyzed. Bronchoalveolar lavage (BAL) fluid and lung biopsy specimens were stained with hematoxylin and eosin and periodic acid-Schiff, visualized by means of electron microscopy, and studied for associated infections. As a control group, BAL fluid and biopsy specimens from 22 patients with SCID caused by other genetic abnormalities were similarly assessed.
RESULTS: Among 16 consecutive patients with ADA deficiency, 7 had BAL fluid containing periodic acid-Schiff-positive surfactant-like material with macrophages engulfing degenerating lamellar bodies and/or lung biopsy specimens with alveolar spaces filled with homogeneous granular eosinophilic material and large macrophages. The lung pathology was typical of PAP. Identification of various pathogens coincided with PAP in 3 of these patients. We have diagnosed PAP among patients with ADA deficiency more commonly in the last 10 years than previously (P= .05), likely reflecting increased awareness of this condition. There were no significant differences in the clinical or immunologic characteristics between patients with ADA deficiency with or without PAP. Similar findings of PAP were not found among patients with SCID caused by other genetic abnormalities (P= .001). ADA coupled to polyethylene glycol or allogeneic hematopoietic stem cell transplantation rapidly corrected this pulmonary complication. PAP seems to have contributed to the death of only 1 patient with ADA deficiency.
CONCLUSIONS: ADA deficiency predisposes to the development of PAP, which could be reversed after enzyme replacement or transplantation.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409989     DOI: 10.1016/j.jaci.2012.02.003

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  24 in total

1.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

Review 2.  How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).

Authors:  Donald B Kohn; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2017-02-14       Impact factor: 8.317

3.  Comparison of elapegademase and pegademase in ADA-deficient patients and mice.

Authors:  L Murguia-Favela; W Min; R Loves; M Leon-Ponte; E Grunebaum
Journal:  Clin Exp Immunol       Date:  2020-02-09       Impact factor: 4.330

4.  Hematopoietic stem cell transplantation for pulmonary alveolar proteinosis associated with primary immunodeficiency disease.

Authors:  Mari Tanaka-Kubota; Koji Shinozaki; Satoshi Miyamoto; Masakatsu Yanagimachi; Tsubasa Okano; Noriko Mitsuiki; Masahiro Ueki; Masafumi Yamada; Kohsuke Imai; Masatoshi Takagi; Kazunaga Agematsu; Hirokazu Kanegane; Tomohiro Morio
Journal:  Int J Hematol       Date:  2017-11-28       Impact factor: 2.490

5.  Chest Radiographs for Distinguishing ADA-SCID from Other Forms of SCID.

Authors:  Martijn V Verhagen; Valentina Trevisan; John Adu; Catherine M Owens; Claire Booth; Alistair Calder
Journal:  J Clin Immunol       Date:  2019-12-19       Impact factor: 8.317

6.  Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening.

Authors:  Morna J Dorsey; Christopher C Dvorak; Morton J Cowan; Jennifer M Puck
Journal:  J Allergy Clin Immunol       Date:  2017-03       Impact factor: 10.793

7.  Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.

Authors:  Denise Carbonaro Sarracino; Alice F Tarantal; C Chang I Lee; Michele Martinez; Xiangyang Jin; Xiaoyan Wang; Cinnamon L Hardee; Sabine Geiger; Christoph A Kahl; Donald B Kohn
Journal:  Mol Ther       Date:  2014-06-13       Impact factor: 11.454

Review 8.  Hematopoietic stem cell transplantation for primary immunodeficiencies.

Authors:  Elizabeth Kang; Andrew Gennery
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-16       Impact factor: 3.722

Review 9.  Imaging Features of Primary Immunodeficiency Disorders.

Authors:  Jose A Rodriguez; Tami J Bang; Carlos S Restrepo; Daniel B Green; Lorna P Browne; Daniel Vargas
Journal:  Radiol Cardiothorac Imaging       Date:  2021-03-25

Review 10.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.